Oral or pulse glucocorticoid use at the onset of giant cell arteritis and its influence on the risk of relapse: a retrospective study
Authors:
- Laura Trives-FolgueraLTLaura Trives-Folguera
- Juan Molina-ColladaJMJuan Molina-Collada
- Katerine LópezKLKaterine López
- Javier RiveraJRJavier Rivera
- Belén Serrano-BenaventeBSBelén Serrano-Benavente
- Ana M. Anzola-AlfaroAAAna M. Anzola-Alfaro
- Isabel CastrejónICIsabel Castrejón
- José María Álvaro-GraciaJÁJosé María Álvaro-Gracia
- Julia Martínez-BarrioJMJulia Martínez-Barrio
- 7 April 2023
- journal article
- research article
- Published by Springer Nature in Rheumatology International
- Vol. 43 (7) , 1333-1340
Abstract
The objective is to investigate whether initial therapy with intravenous methylprednisolone pulses (ivMTP) or oral glucocorticoid (OG) influences the relapse rate in giant cell arteritis (GCA) patients. This is a retrospective observational study of patients with GCA from 2004 to 2021. Demographics, clinical and laboratory variables, cumulative glucocorticoid dose and relapse rate at 6-month follow-up defined according to EULAR recommendations were recorded. Univariate and multivariate logistic regression models were used to determine possible risk factors for relapse. A total of 74 GCA patients were included for analysis (54 (73%) female, mean (SD) age 77.2 (7.4) years). Overall, 47 (63.5%) patients received ivMTP at disease onset and 27 (36.5%) OG. Mean (SD) cumulative prednisone dose (mg) at 6-month follow-up was 3790.7 (1832.7) for patients with ivMTP vs 4298.1 (2930.6) for the OG group, p = 0.37. A total of 15 (20.3%) relapses occurred at 6-month follow-up. Relapse rates did not differ according to the initial therapy (19.1 vs 22.2%, respectively, p = 0.75). In the multivariate analysis, fever at disease onset (OR 4.837; CI 1.1–21.6) and dyslipidemia (OR 5.651; CI 1.1–28.4) were independent predictors for relapse. Initial therapy with ivMTP or OG does not influence the relapse rate of GCA patients. Fever at disease onset and dyslipidemia are independent predictors of disease relapse.Keywords
This publication has 26 references indexed in Scilit:
- Predictors of relapse and treatment outcomes in biopsy-proven giant cell arteritis: a retrospective cohort studyRheumatology, 2015
- Disease Relapses among Patients with Giant Cell Arteritis: A Prospective, Longitudinal Cohort StudyThe Journal of Rheumatology, 2015
- Relapses in Patients With Giant Cell ArteritisMedicine, 2014
- Relapses and Recurrences in Giant Cell ArteritisMedicine, 2011
- Epidemiology of giant cell arteritis and polymyalgia rheumaticaArthritis Care & Research, 2009
- Treatment of giant cell arteritis using induction therapy with high‐dose glucocorticoids: A double‐blind, placebo‐controlled, randomized prospective clinical trialArthritis & Rheumatism, 2006
- Influence of Traditional Risk Factors of Atherosclerosis in the Development of Severe Ischemic Complications in Giant Cell ArteritisMedicine, 2004
- Glucocorticoid therapy in giant cell arteritis: Duration and adverse outcomesArthritis Care & Research, 2003
- A strong initial systemic inflammatory response is associated with higher corticosteroid requirements and longer duration of therapy in patients with giant‐cell arteritisArthritis Care & Research, 2002
- The American College of Rheumatology 1990 criteria for the classification of giant cell arteritisArthritis & Rheumatism, 1990